Big news: Novartis FDA Car T approval is likely coming soon after a Food and Drug Administration advisory panel unanimously recommended approval for Novartis’s leukemia drug tisagenlecleucel. The FDA usually follows its panels’ recommendations.
The big thing though will be price point. Car T is very expensive because it involves personalized treatment. If it’s too expensive, insurance companies won’t cover it.
Novartis FDA Car T
Novartis said that in patients with recurrent leukemia, 75% were still cancer free after CAR-T treatment.
Wells Fargo’s David Maris told clients that this ground-breaking approval is “the most exciting thing I’ve seen in my lifetime.”
CAR-T medicine is a new, personalized treatment which requires taking a patient’s own cells, removing them from the body, reengineering them for immunotherapy, and placing them back in the body.
The official Novartis FDA Car T approval is expected in October 2017.
Novartis Stock Chart
NVS has an ok setup pattern but I’m not really thrilled about it. I feel like we need more of a consolidation and a candle over candle reversal too so we know other buyers are stepping in at this level. There is a very little resistance above the current price. There is a support zone below the current price at 82.96, a stop order could be placed below this zone.
Novartis Stock Review
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. The Novartis Institutes for BioMedical Research with more than 6,000 scientists and physicians worldwide, is the innovation engine of Novartis. NIBR focuses on discovering new drugs that can change the practice of medicine.
Latest posts by Lance Jepsen
- PowerShares Global Clean Energy ETF Exploding Large Players Volume - November 17, 2017
- Top News Stories November 16 2017 - November 16, 2017
- BeiGene Stock Exploding Large Players Volume On Candle Over Candle - November 16, 2017